The company expects the trial to support the submission of a biologics license application with the US Food and Drug Administration in 2026.
Regenxbio’s investigational gene therapy improved muscle function for patients with Duchenne muscular dystrophy (DMD) in a phase 1/2 study. | Regenxbio’s investigational gene therapy improved muscle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback